Surgical Removal of Internal Limiting Membrane and Layering of AAV Vector on the Retina Under Air Enhances Gene Transfection in a Nonhuman Primate
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Purpose: To determine if the surgical removal of the internal limiting membrane (ILM) in nonhuman primates (NHPs) will result in safe and effective transfection of adeno-associated viral (AAV2) vectors using green fluorescent protein (GFP) as a reporter. Methods: Six Macaca fascicularis NHP eyes underwent vitrectomy, ILM peel with layering of 1.7 × 1013 genome copies per milliliter of AAV2-GFP under air. Four control eyes underwent only vitrectomy and pooling under air. The intensity and area transfected was quantified in vivo with fundus autofluorescence (FAF) imaging. NHPs were euthanized 16 weeks postsurgery and immunohistochemical analysis assessed GFP expression at the cellular level. Results: There was a larger area of fluorescence in ILM peeled eyes then in non-ILM peeled eyes (50.7 [33.1-58.4] pixel2 versus 5.1 [0.6-7.6] pixel2, P < 0.01). The intensity of fluorescence was also higher in ILM peeled eyes (10.3 [2.2-18.5] vs. 1.9 [0.6-4.4], P = 0.05). Non-ILM peeled eyes displayed fluorescence confined to the foveal center. Histological sections showed colocalization in the Müller cell layer, ganglion cell layer, and photoreceptor cell layer in the ILM peeled eyes. In non-ILM peeled eyes GFP expression was only in the ganglion cell layer in three eyes and was confined to the immediate vicinity of the fovea. Conclusions: ILM appears to be the predominate barrier to AAV transfection. An efficacious and safe method of AAV2 gene delivery, taking into account the potential need for repeat treatments, appears to be the surgical removal of ILM and layering of AAV under air.v.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 'peel-and-puddle ' surgical technique for depos iting the vector solution directly over the bare inner retinal surface after ILM peeling has been shown to improve transduction, but still requires a complex surgical approach (Comander et al., 2016; Teo et al., 2018).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Teo et al., 2018
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Macular hole surgery with and without internal limiting membrane peeling
Brooks, H. L. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00331-6 · Cited by 642
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., & Weichselberger, A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.004 · Cited by 387 · cited 1×
“Treatment posology dictates frequent intravitreal injections of anti-VEGF agents that may be required over many years to maintain vision and to control the disease process.(15,16) Gene therapy, with its ability to provide longer, sustained protein expression, appears to be a promising alternative solution.”
BackgroundInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Research works printed but not linked: 1
- Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006; 19: 361–372.
Cited by
Yiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Peynshaert, K., Devoldere, J., Minnaert, A.-K., De Smedt, S. C., & Remaut, K. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1565890 · Cited by 92
Soucy, J. R., Aguzzi, E. A., Cho, J. Y., Gilhooley, M. J., Keuthan, C. J., Luo, Z., Monavarfeshani, A., Saleem, M. A., Wang, X., Wohlschlegel, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00655-y · Cited by 91
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 88
Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., Groef, L. D., Moons, L., Özcan, S. Y., Dalkara, D., Smedt, S. C. D., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 70
Zhang, K. Y., & Johnson, T. V. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108545 · Cited by 73
Zhang, K. Y., Tuffy, C., Mertz, J. L., Quillen, S. E., Wechsler, L., Quigley, H. A., Zack, D. J., & Johnson, T. V. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.12.001 · Cited by 62
Gene-Based Therapeutics for Inherited Retinal Diseases
Fenner, B. J., Tan, T., Barathi, V. A., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794805 · Cited by 68
Self-citationDelivering AAV to the Central Nervous and Sensory Systems
Peters, C. W., Maguire, C. A., & Hanlon, K. S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.004 · Cited by 45
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
Advances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
Holthaus, S.-M. K., Aristorena, M., Maswood, R. N., Semenyuk, O., Hoke, J., Hare, A., Smith, A. J., Mole, S., & Ali, R. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.038 · Cited by 41
Modeling complex age-related eye disease
Becker, S., L'Ecuyer, Z., Jones, B. W., Zouache, M. A., McDonnell, F. S., & Vinberg, F. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101247 · Cited by 35
The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases
Davis, J. L. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.08.038 · Cited by 32
Devoldere, J., Wels, M., Peynshaert, K., Dewitte, H., Smedt, S. C. D., & Remaut, K. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.023 · Cited by 32
Vrathasha, V., Nikonov, S. S., Bell, B. A., He, J., Bungatavula, Y., Uyhazi, K. E., & Chavali, V. R. M. (2022) · iScience · doi:10.1016/j.isci.2022.105308 · Cited by 34
Lee, S. H., Yang, J. Y., Madrakhimov, S. B., Park, H. Y., Park, K., & Park, T. K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.008 · Cited by 29
Self-citationGene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
“Our group found that surgical removal of the ILM prior to exposing the retina to vector resulted in more effective transfection, even with the AAV2 serotype (Figure 1) (Teo et al., 2018).”
BackgroundSelf-citationPurdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“A ‘peel-and-puddle ’ surgical technique for depositing the vector solution directly over the bare inner retinal surface after ILM peeling has been shown to improve transduction, but still requires a complex surgical approach (Comander et al., 2016; Teo et al., 2018).”
Müller cells trophism and pathology as the next therapeutic targets for retinal diseases
Arrigo, A., Cremona, O., Aragona, E., Casoni, F., Consalez, G., Dogru, R. M., Hauck, S. M., Antropoli, A., Bianco, L., Parodi, M. B., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101357 · Cited by 29
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
New Method for Efficient siRNA Delivery in Retina Explants: Reverse Magnetofection
Bassetto, M., Sen, M., Poulhès, F., Arango‐González, B., Bonvin, E., Sapet, C., Ueffing, M., & Zelphati, O. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00132 · Cited by 18
Clerck, K. D., Smedt, S. C. D., Remaut, K., & Peynshaert, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113849 · Cited by 11
A journey through the world of vitreous
Ayalon, A., Sahel, J., & Chhablani, J. K. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.06.004 · Cited by 10
Permanent transduction of retinal ganglion cells by rAAV2-retro
Zheng, Y. J., Dilbeck, M. D., Economides, J. R., & Horton, J. C. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109793 · Cited by 6
Fundus imaging of retinal ganglion cells transduced by retrograde transport of rAAV2-retro
Nanjappa, R., Dilbeck, M. D., Economides, J. R., & Horton, J. C. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109084 · Cited by 6
Genes as drugs for glaucoma: latest advances
Borrás, T., Stepankoff, M., & Danias, J. (2023) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001025 · Cited by 7
Toward improved AAV gene therapies for retinal disorders: challenges and advances
Siontas, O., Brown, M., & Ahn, S. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2544497 · Cited by 3
Coster, E. D., Clerck, K. D., Clercq, C. D., Li, W., Punj, D., Vanmeerhaeghe, B., Verdonck, J., Smedt, S. C. D., Braeckmans, K., Hadady, H., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.2.56 · Cited by 3
Intravitreal AAV2 gene delivery to feline retinal ganglion cells
Oikawa, K., Eaton, J. S., Kiland, J. A., Torné, O., Mathu, V., Nickells, R. W., & McLellan, G. J. (2024) · Vision Research · doi:10.1016/j.visres.2024.108519 · Cited by 3
Lee, D., Kwak, G., Johnson, T. V., & Suk, J. S. (2022) · Current Protocols · doi:10.1002/cpz1.607 · Cited by 2
Adeno-associated Viral Vectors in the Retina: Delivering Gene Therapy to the Right Destination
Rudnick, N. D., Kim, L. A., & Comander, J. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000416 · Cited by 1
Baez, H. C., LaPorta, J. M., Walker, A. D., Fischer, W. S., Hollar, R., Patterson, S. S., DiLoreto, D. A., Gullapalli, V. K., & McGregor, J. E. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.25 · Cited by 2
Metadata
- Authors
- Teo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J.
- Affiliations
- National University of Singapore (SG)
- Translational Pre-clinical Model Platform, Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore
- Singapore National Eye Center (SG)
- Lions Eye Institute (AU)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2018-07-17
- Volume
- 59
- Issue
- 8
- Pages
- 3574
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2884599554
- Cited by
- 33
- References
- 47
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (University of Western Australia) (submittedVersion, cc-by)
- National University of Singapore (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- internal limiting membrane, adeno-associated virus type 2, gene therapy, subretinal gene delivery, vitrectomy, air layering, transfection efficiency, retinal gene transfer, non-human primates, Macaca fascicularis, green fluorescent protein, Müller cells, photoreceptors
- MeSH terms
- Animals, Basement Membrane, Disease Models, Animal, Macaca fascicularis, Visual Acuity, Vitrectomy, Genetic Therapy, Gene Transfer Techniques, Epiretinal Membrane, Tomography, Optical Coherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.